Cura Partners Enters European Market With Plata Wellness To Distribute Select CBD Brand

UNITED KINGDOM: Cura Partners, one of the largest cannabis and hemp-based CBD consumer products companies in the world, is officially entering the European market (EU) through a distribution agreement with Plata Wellness.

CuraThe agreement allows Cura’s Select CBD products to be available direct to consumers in legal markets across Europe via the website www.selectcbd.eu. Cura has appointed Plata Wellness Limited (Plata) to assist with its entry into the EU. In addition to Plata’s role as Cura’s inaugural overseas distributor, Plata is also providing a number of other services including order fulfillment, payment processing, and in the future, licensing and manufacturing. This partnership begins with the introductions of Select’s CBD disposable vaporizer cartridges but will, over time, add other legal consumer products including tinctures, gel caps and muscle rubs.

“Cura’s decision to move into Europe is in direct alignment with the company’s mission to be the leading provider of cannabis oil to consumers and brands in legal U.S. and international markets,” said President and Chief Executive Officer Cameron Forni. “I’m proud of the team that made this possible, and look forward to partnering with Plata Wellness to get the Select CBD brand into the hands of consumers across Europe.”

Europe is home to more than 741 million people, more than double the combined population of the United States and Canada. When trying to extrapolate these numbers to account for the potential demand in Europe’s much larger population, there is a crystal-clear reason why established cannabis companies in the United States are now turning their attention to Europe.

“We are delighted to have partnered with Cura, the market leading company in this sector. We are excited to work together to bring the Select brand to prominence in Europe and to supply consumers with these award-winning products,” said Jon Robson, Managing Director at Plata Wellness Limited.

Consumers in the United Kingdom can purchase Select CBD Blends vape pens online at www.selectcbd.eu with additional products coming soon.

Global Cannabis Testing Market – Increasing Use For Medical Purposes To Propel Growth

UNITED KINGDOM: The latest market research report by Technavio on the global cannabis testing market predicts a CAGR of around 12% during the period 2018-2022.

The report segments the global cannabis testing market by product (instruments, consumables, and software) and by geography (the Americas, EMEA, and APAC). It provides a detailed illustration of the major factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Here are some key findings of the global cannabis testing market, according to Technavio researchers:

  • Increasing use of cannabis for medical purposes: a major market driver
  • Emergence of luxury cannabis products: emerging market trend
  • In 2017, the global cannabis testing market was led by the Americas with a market share of more than 54%
  • In 2017, the global cannabis testing market by product was led by the instruments segment with a market share of over 50%

Increasing use of cannabis for medical purposes: a major market driver

The increasing use of cannabis for medical purposes is one of the major factors driving the global cannabis testing market. Cannabis used for medicinal purposes is referred to as medical marijuana or medical cannabis. In this case, the whole, unprocessed cannabis plant or its extracts are used to treat a variety of symptoms and conditions. Medical cannabis contains many compounds that are collectively referred to as cannabinoids. The two main compounds are tetrahydrocannabinol (THC) and Cannabidiol (CBD). Though there are several other types of cannabinoids in cannabis strains, THC and CBD are the most abundant compounds. These compounds mainly address pain symptoms in multiple diseases.

First ‘Seed-to-Sale’ Accounting Case Study On Cannabis Industry

UNITED KINGDOM: Cambridge Judge Business School (CJBS) and cannabis operator and investor White Sheep Corp. announced their collaboration on the first “seed-to-sale” accounting case study on the cannabis industry – “High” Profits From Accounting For Cannabis Plant Inventory – co-authored by Alan Jagolinzer, Michael Miller and Steven Looi. The case study will be taught for the first time today by co-authors Jagolinzer and Miller at CJBS.

This case examines questions raised about financial reporting in one of the world’s fastest growing industries, cannabis, aiming to guide students through the reporting process for an industry that is being legalised by an increasing number of jurisdictions. The case focuses, ultimately, on what key decisions go into deciding the fair value of a cannabis crop and how this is reflected on the financial statements.

Michael Miller, Director of Finance at White Sheep Corp., says: “We are honoured to partner with CJBS on this landmark case study. As the first accounting case to directly address the cannabis industry, this is a strong signal to the academic community that it is time to build cannabis into the curricula. The issues explored in the case will continue to emerge as new jurisdictions and new companies enter the industry. We aim to help investors understand the income statements and make better informed capital allocation choices.”

Alan Jagolinzer, Professor of Financial Accounting at CJBS, says: “CJBS is partnering with global business experts to create and enhance complex, innovative, and pertinent academic curriculum to develop students for business leadership. We are very excited to join White Sheep in creating the world’s first accounting case study on the cannabis industry, which is seeing enormous capital growth despite considerably complex and confusing financial reporting. I can see why investors might want to consider publicly-traded cannabis companies. However, I highly doubt they understand the accounting because of the unique rules for agricultural inventory. This case will certainly liven up our discussions of financial accounting and help the professionals of tomorrow to start building these skills today.”

White Sheep was evaluating the financials of several of the top publicly traded cannabis companies when they identified recurring gross margins in excess of 100% on the income statements. Miller and Looi realized this could not be the norm for any company. To explain the exceptional circumstance, they focused on how cannabis plants are treated under IFRS, the accounting reporting standards which govern Canadian public companies. This inspired an article in February 2017 to serve as a healthy warning to investors looking to pile in based purely on the ‘profitability’ of these companies.

 

The Nutraceuticals Market Is Expected To Grow To $275 Billion By 2021

UNITED KINGDOM:  Humans have been consuming choice foods for their medical benefits for millennia. The ancient Egyptians had over 800 known pharmacological treatments for disease, of which 160 were plant products – including compounds being investigated for use in disease today, such as cannabis Historically, herbal medicine utilized many compounds that are now considered nutraceuticals. For instance, bitter apple, Citrullus colocynthis, is described in ancient medical texts, and has been shown to have positive efficacy in clinical trials for uses in cancer and diabetes.

Nutraceuticals market is growing and diversifying rapidly. These products are linked by the fact that they are dietary products that have some degree of either purported or clinically evidenced medical benefit. However, the market lacks a clear definition of what constitutes a nutraceutical, with the term covering a spectrum of products from prescription-only medical foods to widely available consumer supplements.

KPMG forecast that the nutraceuticals market will be worth around $250 billion by 2018, and while the exact scope of what is considered a nutraceutical is broad and variable, the products identified in the KPMG report largely fell within the GBI definition of nutraceuticals. The value of the nutraceuticals industry is over 25% of the value of the pharmaceutical industry, and under 5% of the value of the food industry. Analysts have predicted about 7.3% compound annual growth rate (CAGR) for nutraceuticals from 2015 to 2021, with the market expected to be worth over $275 billion by 2021. This compares favorably with the CAGR of around 4% witnessed from 2002 to 2010.

The report “Nutraceuticals: New Applications for Probiotics, Genetic Modification and Diet as Products Make Gains in Rx Territory” provides key industry perspective on the nutraceuticals industry from a large survey of over 150 food and pharmaceutical industry professionals, both within and outside of the nutraceuticals sector. Those involved in the industry were found to mostly believe in the value propositions of nutraceuticals, and expected their company to increase its level of investment in the area. In contrast, for those not involved with nutraceuticals the opposite was generally true.

Scope
– How can the nutraceuticals sector be defined in general, and what types of product does it include?
– What are the key strategies used in marketing and developing some of the leading nutraceutical products?
– What are the key companies involved in nutraceuticals?
– What are some of the key upcoming products, companies and research trends within nutraceuticals?
– How does the regulatory landscape for different types of nutraceutical vary in key territories?
– What factors have hindered the growth of the nutraceuticals market?
– How can companies grow successfully within the nutraceuticals market?

Reasons to buy
– Understand the complex differences in the regional regulation of nutraceuticals, and how they shape the market
– Understand key future trends in the nutraceuticals market
– Gain an understanding of the industry perspective on critical aspects of the nutraceuticals industry, such as drivers, barriers, promising geographies and the value propositions of products
– Understand the strategies of key players from the food and pharmaceutical industries that are involved in the nutraceuticals market

Download the full report. 

Global CBD Oil Market To Grow At 39.19% CAGR In 2017-2021.

UNITED KINGDOM: Cannabidiol (CBD) is one of the hundreds of cannabinoids found in the Cannabis sativa plant. CBD oil can be derived from two different species of cannabinoids: marijuana and hemp. The Americas dominated the global CBD oil market in 2016, followed by EMEA and APAC.

Hemp-based CBD oil products have a lower delta-9 tetrahydrocannabinol (THC) concentration, whereas marijuana-derived CBD oil products have a relatively high concentration of THC.

Technavio’s report, Global CBD Oil Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The firm’s analysts forecast the global CBD oil market to grow at a CAGR of 39.19% during the period 2017-2021.

Europe’s Legal Cannabis Market Is A €56 Billion Opportunity

UNITED KINGDOM: A new report from industry advisors, Prohibition Partners, suggests that Europe will become the largest legal cannabis market in the world once all countries have introduced legislation and regulation over the next five years.

Cannabis is set to become the major global industry of the post-digital generation. It will drive economic and employment growth as well as having a significant impact on a wide range of social issues.

The impressive financial performance of North American cannabis companies is already drawing in institutional investors – even before US federal legislation.

However, Europe is quickly catching up with a record number of countries introducing medical cannabis legislation already this year. Most governments understand the medical and tax benefits so are moving fast to position correctly for this opportunity. Buoyed by a shift in legislation and ground breaking returns, the European cannabis industry represents a very unique and rewarding opportunity.

The European Cannabis Report™ (2nd Edition) explores the complex regulatory environment while providing a detailed analysis of 15 key markets across the medical, recreational and industrial sectors.

 

Top 3 Drivers Of North American Cannabis Packaging Market

UNITED KINGDOM: Technavio market research analysts forecast the cannabis packaging market in North America to grow at a CAGR of more than 10% during the forecast period, according to their latest report.

The market study covers the present scenario and growth prospects of the cannabis packaging market in North America for 2017-2021. The report also lists rigid packaging and flexible packaging as the two major segments based on packaging type. The rigid packaging segment dominated the market with close to 62% of the market share in 2016.

 

Study: CBD Administration Reduces Blood Pressure

UNITED KINGDOM: Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

Investigators from the University of Nottingham assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction). Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress. Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

Authors concluded: “Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

 

Clinical Trial: THCV Lowers Blood Sugar Levels In Type 2 Diabetics

UNITED KINGDOM: The administration of THCV (tetrahydrocannabivarin), a non-psychoactive component of cannabis, is positively associated with glycemic control in type 2 diabetics, according to the randomized, placebo-controlled data published in the journal Diabetes Care.

Investigators from the University of Nottingham, School of Medicine assessed the twice daily administration of various cannabinoids (CBD or THCV or CBD and THCV in combination) versus placebo over a period of 13 weeks in 62 non-insulin dependent subjects with type 2 diabetes.

Authors reported that the administration of THCV alone “significantly decreased fasting plasma glucose” levels and improved pancreatic cell function. By contrast, other treatment therapies failed to show detectable metabolic effects.

Investigators concluded, “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Population-based observational studies have previously reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control compared to those without a history of marijuana use.

MPs Set To Debate Legalizing Cannabis On October 12

UNITED KINGDOM:  MPs are set to debate whether the UK should legalize the production, sale and possession of cannabis after a petition calling for drug law reform attracted more than 200,000 signatures. The government confirmed a debate led by Labour MP Paul Flynn will take place in Westminster Hall on 12 October. Flynn, MP for Newport West, has campaigned for the cannabis reform for 25 years and is also a long-time advocate of medical marijuana.

The debate is in response to a popular parliamentary petition that argued legalizing cannabis could bring in “£900m ($1.3 Billion) in taxes every year, save £400m ($614 Million) on policing cannabis and create over 10,000 new jobs”. The petition took just four days to amass 125,000 signatures after it was launched in July.

However, it is unlikely the debate will have any effect on the current drugs laws. In response to the petition, a government spokesperson said: “Substantial scientific evidence shows cannabis is a harmful drug that can damage human health. There are no plans to legalize cannabis as it would not address the harm to individuals and communities.”